A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors
LoRusso, Patricia, Rasco, Drew W., Shapiro, Geoffrey, Mita, Alain C., Azad, Nilofer Saba, Swiecicki, Paul, El-Khoueiry, Anthony B., Gandara, David R., Kummar, Shivaani, Tanajian, Hovig, Taylor, Jaruwan, Bottone, Frank G, Toguchi, Marchi, Hindley, Chris, Chan, Danna, Oganesian, Aram, Keer, Harold N., Dao, Kim-Hien T, Sullivan, Ryan J., Spira, Alexander I.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article